ase. We anticipate that subsequent events and developments will cause our expectations and beliefs to change. However, while we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, business development transactions, joint ventures or investments that we may make. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this release.
ZYFLO CR(R), ZYFLO(R), AlleRx(R), Deconsal(R), Balacet(R) and HyoMax(R) are trademarks or service marks of Cornerstone Therapeutics Inc. SPECTRACEF is a trademark of Meiji Seika Kaisha, Ltd. and is licensed to the Company.
FINANCIAL TABLES FOLLOW
CORNERSTONE THERAPEUTICS INC.
CONSOLIDATED STATEMENTS OF INCOME
(In thousands, except share and per share data)
Year Ended December 31,
Net revenues $64,867 $28,071
Costs and expenses:
Cost of product sales (exclusive of
amortization of product rights) 5,951 3,300
Sales and marketing 16,993 10,391
Royalties 16,193 3,409
General and administrative 9,757 4,177
Research and development 3,838 948
Amortization of product rights 1,334 3,160
Page: 1 2 3 4 5 6 7 8 9 10 11 12 Related biology technology :1
|SOURCE Cornerstone Therapeutics Inc.|
Copyright©2009 PR Newswire.
All rights reserved
. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call2
. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance3
. Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders4
. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Tuesday, March 24, 20095
. Cell Therapeutics Announces Filing of Form 10-K6
. Horizon Therapeutics Selected to Present at InsideVentures Debut Investor Conference March 25-26, Santa Barbara, California7
. Oxygen Biotherapeutics, Inc. Expands Board of Directors8
. Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics9
. Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference10
. Nile Therapeutics Announces Information in Compliance With NASDAQ Marketplace Rule 4350 and Reiterates 2009 Objectives11
. Medarex to Present at the Needham Cancer Therapeutics Conference